摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(1,2,4-triazol-1-yl)azetidine hydrochloride | 1251925-09-3

中文名称
——
中文别名
——
英文名称
3-(1,2,4-triazol-1-yl)azetidine hydrochloride
英文别名
3-(1-1,2,4-triazolyl)azetidine hydrochloride;1-(azetidin-3-yl)-1,2,4-triazole;hydrochloride
3-(1,2,4-triazol-1-yl)azetidine hydrochloride化学式
CAS
1251925-09-3
化学式
C5H8N4*ClH
mdl
——
分子量
160.606
InChiKey
SPVBOJBSURLBDS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.16
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    42.7
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    3-(1,2,4-triazol-1-yl)azetidine hydrochloride5-氨基-1-环丙基-6,7,8-三氟-4-氧代-1,4-二氢-3-喹啉羧酸吡啶1,8-二氮杂双环[5.4.0]十一碳-7-烯 为溶剂, 以95 mg (94%)的产率得到5-Amino-1-cyclopropyl-6,8-difluoro-7-[3-(1,2,4-triazol-1-yl)azetidin-1-yl]-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
    参考文献:
    名称:
    7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
    摘要:
    取代喹啉化合物及其中间体,生产这些化合物和中间体的过程,使用这些化合物的药物组合物,使用这些化合物治疗细菌感染的方法,以及使用这些化合物进行消毒的方法。
    公开号:
    US05342846A1
  • 作为产物:
    描述:
    N-Benzhydryl-3-(1,2,4-triazol-1-yl)azetidine 、 盐酸 crude product 、 methanol-ether 作用下, 以 乙醇 为溶剂, 反应 48.0h, 以to afford 0.235 g of white solid的产率得到3-(1,2,4-triazol-1-yl)azetidine hydrochloride
    参考文献:
    名称:
    7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
    摘要:
    取代的喹啉化合物及其中间体,制备这些化合物和中间体的过程,使用这些化合物的制药组合物,使用这些化合物治疗细菌感染的方法,以及使用这些化合物进行消毒的方法。
    公开号:
    US05342846A1
点击查看最新优质反应信息

文献信息

  • NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF
    申请人:WAKUNAGA PHARMACEUTICAL CO., LTD.
    公开号:US20200062752A1
    公开(公告)日:2020-02-27
    It is intended to provide a novel compound having high antitumor activity and low toxicity to normal cells. The present invention provides a pyridone carboxylic acid derivative represented by the following formula (1) or a salt thereof wherein R 1 represents a hydrogen atom, a halogen atom or the like; R 2 represents a hydrogen atom, a halogen atom or the like; R 3 to R 6 each represent a hydrogen atom or the like; R 7 represents a hydrogen atom or the like; R 8 represents a hydrogen atom, a halogen atom, the following formula (a) (wherein R a1 and R a2 each represent a hydrogen atom, a hydroxy group, an optionally substituted lower alkyl group or the like) or the like, or R 7 and R 8 together represent —N—OR 10 (wherein R 10 represents a hydrogen atom, an optionally substituted lower alkyl group, or an aralkyl group), or R 7 and R 8 form an optionally substituted 4- to 6-membered saturated hetero ring together with the adjacent carbon atom, or the like; R 9 represents a hydrogen atom or the like; X represents a nitrogen atom or the like; and Y represents a nitrogen atom or the like.
    本发明旨在提供一种具有高抗肿瘤活性和低毒性对正常细胞的新型化合物。本发明提供一种由以下式(1)表示的吡啶酮羧酸生物或其盐,其中R1代表氢原子、卤素原子或类似物;R2代表氢原子、卤素原子或类似物;R3至R6各自代表氢原子或类似物;R7代表氢原子或类似物;R8代表氢原子、卤素原子、以下式(a)(其中Ra1和Ra2各自代表氢原子、羟基、可选择取代的低烷基基团或类似物)或类似物,或者R7和R8一起代表—N—OR10(其中R10代表氢原子、可选择取代的低烷基基团或芳基烷基基团),或者R7和R8与相邻碳原子一起形成可选择取代的4-至6元饱和杂环,或类似物;R9代表氢原子或类似物;X代表氮原子或类似物;Y代表氮原子或类似物。
  • Carbapenem derivatives, their preparation and their use as antibiotics
    申请人:Sankyo Company, Limited
    公开号:US05866564A1
    公开(公告)日:1999-02-02
    Compound of formula (I): ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or --C(.dbd.NH)R.sup.0 where R.sup.0 is hydrogen or C.sub.1 -C.sub.6 alkyl; A is ##STR2## R.sup.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or --C(.dbd.NH)R.sup.6 where R.sup.6 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.7 cycloalkyl; R.sup.3 and R.sup.4 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, hydroxy, carboxy, cyano, --CO.NR.sup.a R.sup.b, --OCO.NR.sup.a R.sup.b or --NR.sup.a R.sup.b, where R.sup.a and R.sup.b are independently hydrogen or C.sub.1 -C.sub.6 alkyl; R.sup.20", R.sup.21', and R.sup.22" are independently hydrogen or C.sub.1 -C.sub.6 alkyl or R.sup.20" and R.sup.21" or R.sup.20" and R.sup.22" together form a heterocyclic group; R.sup.23" and R.sup.24" are independently hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; n is 1, 2 or 3; and n.sup.3" is 1, 2 or 3. The compounds are antibiotics which are resistant to dehydropeptidase I, and are useful for the treatment of microbial infections.
    化合物的公式(I):##STR1## 其中R.sup.1是氢,C.sub.1-C.sub.6烷基,C.sub.2-C.sub.6烯基,C.sub.2-C.sub.6炔基或--C(.dbd.NH)R.sup.0,其中R.sup.0是氢或C.sub.1-C.sub.6烷基; A是##STR2## R.sup.2是氢,C.sub.1-C.sub.6烷基,C.sub.2-C.sub.6烯基,C.sub.2-C.sub.6炔基或--C(.dbd.NH)R.sup.6,其中R.sup.6是氢,C.sub.1-C.sub.6烷基或C.sub.3-C.sub.7环烷基; R.sup.3和R.sup.4独立地是氢,C.sub.1-C.sub.6烷基,卤素,羟基,羧基,基,--CO.NR.sup.aR.sup.b,--OCO.NR.sup.aR.sup.b或--NR.sup.aR.sup.b,其中R.sup.a和R.sup.b独立地是氢或C.sub.1-C.sub.6烷基; R.sup.20",R.sup.21'和R.sup.22"独立地是氢或C.sub.1-C.sub.6烷基,或R.sup.20"和R.sup.21"或R.sup.20"和R.sup.22"一起形成一个杂环基团; R.sup.23"和R.sup.24"独立地是氢,卤素或C.sub.1-C.sub.6烷基; n为1, 2或3; n.sup.3"为1, 2或3。这些化合物是对去氢肽酶I具有抗性的抗生素,可用于治疗微生物感染。
  • Antimicrobial carbapenem derivatives, their preparation and their therapeutic use
    申请人:SANKYO COMPANY LIMITED
    公开号:EP0560613A1
    公开(公告)日:1993-09-15
    Compounds of formula (I) : (in which R1 is hydrogen or methyl, R2 is hydrogen, optionally substituted aliphatic hydrocarbon or acylimidoyl, R3 is hydrogen or an ester group, and Q is an optionally quaternized nitrogen-containing group) are useful antibiotics which are resistant to dehydropeptidase I, and are thus useful for the treatment of many microbial infections.
    式(I)化合物: (其中 R1 是氢或甲基,R2 是氢、任选取代的脂肪族烃或酰亚胺基,R3 是氢或酯基,Q 是任选季化的含氮基团)是对脱肽酶 I 具有抗性的有用抗生素,因此可用于治疗多种微生物感染。
  • 7-SUBSTITUTED-6-FLUORO-1,4-DIHYDRO-4-OXO-QUINOLINE-3-CARBOXYLIC ACID COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS
    申请人:SYNPHAR LABORATORIES INC.
    公开号:EP0561850A1
    公开(公告)日:1993-09-29
  • US5342846A
    申请人:——
    公开号:US5342846A
    公开(公告)日:1994-08-30
查看更多